In short
Rosai-Dorfman syndrome is a rare condition that involves an overgrowth of immune cells called histiocytes, most commonly affecting lymph nodes and skin. While this disorder is usually not life-threatening, managing its symptoms and deciding when treatment is needed requires careful consideration, as the disease behaves differently in each person.
Key points
- Many patients with Rosai-Dorfman syndrome never need treatment—the disease often resolves spontaneously without medical intervention.
- When treatment is necessary, surgical removal is the most common first approach, particularly effective for localized disease affecting a single area.
- Corticosteroids help more than half of patients who receive them, but balancing effectiveness against side effects is an ongoing challenge.
- Recent genetic discoveries showing mutations in the MAP kinase pathway have transformed understanding of the disease and opened doors to targeted therapies.
- Clinical trials are investigating innovative treatments including MEK inhibitors and immunotherapy agents like siltuximab that have shown promise in difficult cases.
- About one in three treated patients experiences disease recurrence, highlighting the importance of long-term follow-up monitoring.
- The rarity of Rosai-Dorfman syndrome means there's no universally approved treatment protocol—decisions are highly individualized based on disease location, severity, and patient characteristics.
- International collaboration through organizations like the Histiocyte Society is accelerating research progress despite the disease's rarity, with only about 100 new U.S. cases diagnosed annually.
How Doctors Approach Treatment of Rosai-Dorfman Syndrome
Treating Rosai-Dorfman syndrome is not a one-size-fits-all process. The main goals of treatment are to control symptoms, reduce the accumulation of excess histiocytes (a type of white blood cell) in affected tissues, and improve the patient's quality of life. Histiocytes normally help fight infections, but when they grow out of control, they can cause swelling in lymph nodes or damage to organs.
Because Rosai-Dorfman syndrome is rare—affecting about 1 in every 200,000 people, with only around 100 new cases diagnosed in the United States each year—there is no single approved treatment recommended by all medical organizations. Instead, doctors choose treatment based on where the disease is located in the body, how severe the symptoms are, and whether the condition is improving or worsening over time.
In many cases, Rosai-Dorfman syndrome resolves on its own without any medical intervention. Many patients experience symptoms that fade away naturally, which is why doctors sometimes choose a "watch and wait" approach. However, some individuals develop persistent or aggressive disease that requires active treatment. The unpredictable nature of this condition makes it challenging to decide the best timing and type of therapy for each patient.
The treatment landscape includes standard therapies that have been used for years as well as newer, experimental approaches being tested in clinical trials. These research studies are exploring innovative therapies that target the underlying biological processes causing the disease, offering hope for patients who do not respond to traditional treatments.
Standard Treatment Options for Rosai-Dorfman Syndrome
Standard treatment for Rosai-Dorfman syndrome varies widely depending on whether the disease affects only lymph nodes or also involves other organs. The choice of therapy also depends on the severity of symptoms and whether the disease is causing organ damage or impairing normal body functions.
Observation Without Treatment
For many patients, especially those with mild symptoms or disease limited to one area, doctors recommend careful monitoring without immediate treatment. This is because Rosai-Dorfman syndrome often resolves on its own. In one major study of 64 patients, many experienced spontaneous improvement over time. The decision to wait rather than treat is common when the histiocyte overgrowth is not causing significant problems or threatening vital organ function.
Surgical Removal
When Rosai-Dorfman syndrome affects a single, accessible location—such as a skin nodule or a specific lymph node—doctors often recommend surgical removal. According to research from the Mayo Clinic, surgical excision was the most commonly used first-line treatment, performed in 38% of cases. This approach is particularly effective for localized disease where the excess histiocytes can be completely removed. Surgery can provide immediate relief from symptoms caused by swelling or pressure on nearby structures.
For patients with skin involvement—the most common site outside lymph nodes—surgical removal of nodules or lumps can be both diagnostic and therapeutic. The removed tissue is examined under a microscope to confirm the diagnosis while simultaneously treating the visible problem.
Corticosteroids
Systemic corticosteroids are medications that reduce inflammation throughout the body. They were the second most common first-line treatment in clinical practice, used in 27% of patients. Corticosteroids work by suppressing the immune system and reducing the activity of histiocytes. In studies, these medications led to a response in 56% of cases, meaning that more than half of patients experienced improvement in their symptoms or reduction in disease activity.
Corticosteroids are typically prescribed as pills taken daily for weeks or months. The duration of treatment depends on how well the patient responds and whether the disease returns when the medication is reduced or stopped. While effective for many people, corticosteroids can cause side effects when used for extended periods. These may include weight gain, mood changes, increased blood sugar levels, weakened bones, increased risk of infections, and changes in appearance such as facial swelling.
Other Systemic Therapies
When surgery is not possible or when the disease affects multiple areas of the body, doctors may prescribe other systemic medications. These are drugs that travel through the bloodstream to reach disease throughout the body. Several different types of medications have been tried in Rosai-Dorfman syndrome, although none are specifically approved for this condition.
Cladribine is a chemotherapy drug that has shown promise in treating Rosai-Dorfman syndrome. In the Mayo Clinic study, it was the most commonly used systemic agent among patients who needed treatment beyond surgery or corticosteroids. Cladribine works by targeting and reducing the number of certain immune cells, including the histiocytes that cause problems in this disease. Among six patients treated with cladribine, 67% experienced an overall response, meaning their symptoms improved or their disease stabilized. This medication is given as an injection or infusion into a vein, typically over several treatment cycles.
The timing of when to start these more intensive treatments is a difficult decision. Doctors typically reserve them for patients whose disease is progressing despite simpler approaches or for those whose symptoms are significantly affecting their daily life or organ function.
Radiation Therapy
In rare situations, doctors may use radiation therapy, which uses high-energy beams to destroy cells in a specific area. This approach is rarely chosen but may be considered for disease in critical locations that cannot be surgically removed and is not responding to medications.
Innovative Treatments Being Tested in Clinical Trials
Recent scientific discoveries have opened new avenues for treating Rosai-Dorfman syndrome. In the last decade, researchers discovered that cancer-causing genetic changes, called mutations, occur in the MAP kinase pathway in about 50% of cases with Rosai-Dorfman syndrome. This pathway is a series of proteins inside cells that send signals controlling cell growth and division. When mutations occur in this pathway, cells can grow out of control. Because of these findings, the World Health Organization recognized Rosai-Dorfman syndrome as a blood cancer in 2022, even though it is usually not life-threatening.
This understanding of the disease's biology has led to the development of targeted therapies—medications designed to block specific molecular abnormalities driving the disease. These treatments are currently being evaluated in research studies at medical centers in the United States, Europe, and other parts of the world.
Targeted Therapies for Genetic Mutations
Some patients with Rosai-Dorfman syndrome have specific mutations in genes such as MAP2K1 (also known as MEK1), which is part of the MAP kinase pathway. Researchers have identified that three patients in one study had overlap between Rosai-Dorfman disease and another histiocytic disorder called Erdheim-Chester disease, and two of these patients were found to have MAP2K1 mutations. This discovery suggests that medications targeting this pathway might be effective.
Clinical trials are investigating drugs called MEK inhibitors, which block the abnormal signals from mutated MAP2K1 and related genes. These medications are designed to specifically interfere with the molecular processes that cause histiocytes to overgrow. By blocking these signals, the drugs aim to slow or stop disease progression while causing fewer side effects than traditional chemotherapy, which affects all rapidly dividing cells in the body.
These targeted therapies are typically studied in phases. Phase I trials focus primarily on safety, determining the appropriate dose and identifying potential side effects in a small number of patients. Phase II trials evaluate whether the treatment actually works—whether it reduces histiocyte accumulation, shrinks enlarged lymph nodes, or improves symptoms. Phase III trials compare the new treatment with existing standard therapies to determine if it offers advantages in effectiveness or tolerability.
Immunotherapy Approaches
Another promising area of research involves using the body's own immune system to fight the disease. One such approach used siltuximab, an antibody that blocks interleukin-6 (IL-6), a protein that promotes inflammation and may play a role in Rosai-Dorfman syndrome. In one published case, a 64-year-old man with widespread Rosai-Dorfman disease affecting lymph nodes, kidneys, and bones did not respond to multiple other treatments. After receiving siltuximab, which is given as an infusion into a vein, he experienced significant improvement. His symptoms resolved, and imaging studies showed dramatic reduction in the size of masses throughout his body.
The rationale for using IL-6 blockers came from observations that patients who responded to cladribine treatment showed normalization of IL-6 levels, which had been elevated before treatment. This suggested that reducing IL-6 activity might help control the disease. Siltuximab works by binding to IL-6 and preventing it from attaching to cells, thus blocking the inflammatory signals that may contribute to histiocyte overgrowth.
This type of immunotherapy represents a different strategy from traditional chemotherapy or targeted therapies. Instead of directly killing histiocytes or blocking growth signals inside cells, it modulates the inflammatory environment that allows the disease to flourish. Because this approach was successful in at least one patient with severe, treatment-resistant disease, researchers are interested in studying it further in larger clinical trials.
Patient Eligibility for Clinical Trials
Clinical trials testing new treatments for Rosai-Dorfman syndrome typically have specific eligibility requirements. Researchers usually look for patients whose disease has not responded to standard treatments or who have aggressive disease affecting multiple organs. The trials may also require genetic testing to identify specific mutations that the experimental drug is designed to target. Patients interested in participating in clinical trials should discuss this option with their healthcare team, who can help determine if any suitable studies are available and whether the patient meets the enrollment criteria.
Trials are conducted at specialized medical centers that have expertise in treating rare blood disorders. While some trials may be limited to specific countries or regions, the international collaboration among researchers means that knowledge gained from trials conducted anywhere can eventually benefit patients worldwide.
How Long Does Treatment Last?
The duration of treatment for Rosai-Dorfman syndrome varies considerably depending on the approach used and how the individual responds. For patients who undergo surgical removal of affected tissue, the procedure itself is a one-time intervention, though follow-up monitoring continues for months or years to watch for recurrence.
Corticosteroid treatment typically lasts weeks to months. Doctors usually start with a higher dose and gradually reduce it over time while monitoring whether the disease remains under control. Some patients may need repeated courses of corticosteroids if symptoms return. The challenge with this medication is balancing effectiveness against the side effects that become more problematic with long-term use.
Chemotherapy agents like cladribine are usually given in cycles, with treatment periods followed by rest periods. A typical course might involve several cycles over months, with ongoing evaluation to determine whether additional treatment is needed. For patients in clinical trials testing targeted therapies or immunotherapy, the duration depends on the specific study protocol and how well the treatment is working. Some experimental treatments are continued as long as they are effective and not causing unacceptable side effects.
Most Common Treatment Methods
- Observation without immediate intervention
- Careful monitoring for patients with mild symptoms or localized disease
- Appropriate when disease is not causing organ damage or significant symptoms
- Regular follow-up appointments to watch for disease progression
- Surgical excision
- Removal of affected lymph nodes, skin nodules, or other accessible tissue
- Most commonly used first-line treatment, performed in 38% of patients
- Particularly effective for localized disease in a single area
- Corticosteroid therapy
- Oral medications that reduce inflammation and suppress immune system activity
- Second most common first-line treatment, used in 27% of patients
- Response rate of 56% in reducing symptoms or disease activity
- Potential side effects include weight gain, mood changes, increased blood sugar, and weakened bones
- Chemotherapy with cladribine
- Most commonly used systemic agent for patients needing treatment beyond surgery or corticosteroids
- Given as injection or infusion into a vein over several treatment cycles
- Overall response rate of 67% among treated patients
- Works by reducing the number of histiocytes causing disease
- Targeted therapies under investigation
- MEK inhibitors that block abnormal signals from mutations in the MAP kinase pathway
- Designed to specifically interfere with molecular processes causing histiocyte overgrowth
- Currently being tested in clinical trials at specialized medical centers
- Aim to provide effective treatment with fewer side effects than traditional chemotherapy
- Immunotherapy approaches
- Siltuximab, an antibody that blocks interleukin-6 (IL-6), a protein promoting inflammation
- Given as an infusion into a vein
- Successful in treating at least one case of severe, treatment-resistant disease
- Modulates inflammatory environment rather than directly killing cells
- Radiation therapy
- Uses high-energy beams to destroy cells in a specific area
- Rarely used but may be considered for disease in critical locations
- Option when surgery is not possible and medications are not effective
